Lopinavir/Ritonavir (LPV/r) Tablet in HIV Infected Children

Pharmacokinetics of Low- Dose Lopinavir/Ritonavir Tablet Formulation HIV-1 Infected Children

To study the pharmacokinetics of low-dose lopinavir/ritonavir tablet in HIV-1 infected Thai children.

This is an open-label, single arm study to compare standard dose with a new tablet formulation of a lower dose of lopinavir/ritonavir in HIV-1 infected children.

Inclusion Criteria:

1. HIV infection
2. Age < 18 years old
3. BW > 25 kg
4. HIV RNA viral load < 50 copies within 6 months
5. Written informed consent

Exclusion Criteria:

1. Active opportunistic infection
2. Relevant history or current condition, illness that might interfere with drug absorption, distribution, metabolism or excretion.
3. Use of concomitant medications that may interfere with the pharmacokinetics of lopinavir/ritonavir